In a recently reported phase I clinical trial of DMU-C5754A (an anti-MUC16 antibody/mitotic toxin MMAE drug conjugate), objective responses were observed in 5 out of 44 patients diagnosed with advanced/recurrent platinum-resistant ovarian cancer [30]. This evidence concerns the gene MUC16 and ovarian cancer.